Here’s what you should know.
1. In November 2017, Valeant reported its third quarter performance. The company posted a profit in the quarter and its value increased 43 percent by the end of 2017, but revenues sank 10.5 percent.
2. The Fool anticipates revenues will continue to sink as Valeant continues to lose its loss of exclusivity for several key products.
3. The sale of several noncore assets is also expected to hit revenues, the largest being iNova Pharmaceuticals. Valeant is expected to lose $195 million in revenue from the sale.
4. Still the Fool said Valeant’s high-performing holdings, its Bausch + Lomb and international segments grew in the third quarter, with growth expected for the fourth quarter.
5. Valeant’s gastrointestinal products also rebounded to post solid year-over-year sales growth.
6. Although Mr. Papa is dedicated to righting the ship, the Fool reports, “the jury is still out as to whether Valeant’s turnaround has legs. And there’s a long way to go before the company moves from turnaround story to transformation story.”
More articles on supply chain:
Pain Treatment Centers of America buys Arkansas Surgery & Endoscopy Center — 4 insights
Struggling to stay independent — Ohio physicians struggle to remain unaffiliated
Physicians still spend more time with EHRs than with patients — 5 study insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.